HAYWARD, Calif.--(BUSINESS WIRE)--
Impax Laboratories, Inc. (NASDAQ: IPXL) held its 2012
Annual Meeting of Stockholders today in San Mateo, California. Impax
stockholders elected to a one-year term each of the seven nominees for
director named in the Company’s proxy statement, approved, on an
advisory basis, the compensation of the Company’s named executive
officers as described in the proxy statement (“say-on-pay” vote) and
ratified the appointment of KPMG LLP as independent auditors for the
fiscal year ending December 31, 2012.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical
company applying its formulation expertise and drug delivery technology
to the development of controlled-release and specialty generics in
addition to the development of branded products. Impax markets its
generic products through its Global Pharmaceuticals division and markets
its branded products through the Impax Pharmaceuticals division.
Additionally, where strategically appropriate, Impax has developed
marketing partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a full
range of capabilities in its Hayward, Philadelphia and Taiwan
facilities. For more information, please visit the Company's Web site
Source: Impax Laboratories, Inc.